Excited to introduce our Cell Reports Medicine Cell Reports Medicine Cell Press article with the features of overextended #healthy #lifespan vs common #chronological #time: The story of a record-breaking #supercentenarian in a world burdened by #aging-related diseases.

My microbiome is super hungry too often..

19 antibody drug conjugates approved globally, 15 is USA, over 400 ADCs in development, new generation of ADCs under investigation. Dr. Daruka Mahadevan on pre-clinical consideration in ADC Development.

For ESR1-mutated breast cancer, we now have Elacestrant and Imlunestrant approved. Vepdegestrant is pending approval. Definitive conclusions cannot be drawn from cross-trial comparisons but this is what we have in hand. Look forward to combo options! #OncTwitter #bcsm

🏅Optimal treatment sequencing after CDK4/6i + ET in HR+/HER2− MBC remains unclear due to lack of head-to-head trials 🤔 💻We conducted a systematic review & NMA to guide evidence-based decisions. 📰Read more: authors.elsevier.com/sd/article/S25… OncoAlert OncoDaily eClinicalMedicine – The Lancet Discovery Science

What happens to an ADC after its infusion? How does it interact with tumor & immune cells, what causes response & resistance? Take a deep dive in the molecular world of ADCs though our last review, led by Alfred Zippelius and published in Nature Reviews Cancer. nature.com/articles/s4156…

New Study 👉Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA. 🔓pubmed.ncbi.nlm.nih.gov/40930104/ Key Highlights ⬇️ • Paired-sample analysis identifies RTK-RAS and TP53 as frequently mutated pathways • FGFR2 and FGFR4 alterations are

Current dilemma; what to prioritize- omit SLNB or omit adjuvant radiation therapy?

Very interesting data. Not sure 5% ILD in the AC-THP arm is reasonable... Too much awareness?

More evidence that maintenance HP + targeted therapy improves PFS in HER2+ MBC. Originally with palbo/PATINA, now with tucatinib in HER2CLIMB-05 pfizer.com/news/press-rel…

ESMO HANDBOOK OF CANCER GENETICS AND GENOMICS #ESMO25 List of Actionable Genes and the FDA-approved Molecularly Matched Drugs👇

First-in-human data from 6 ADCs will be released at #ESMO25 #ESMOAmbassadors 👇

How do adjuvant CDK4/6i impact the biology of breast cancer that recurs? Angie DeMichele highlights our RW study, led by Chiara Corti, which found 50% of pts losing ER expression and having short 1L PFS if relapsing after abema. Published in ESMO Open #ESMO25 #ESMOAmbassadors

50 mg pembro!

Chemo-free option for neoadj tx in early ER+/HER2+ annalsofoncology.org/article/S0923-…

#ESMO25 EVeRa (Phase III): Giredestrant + everolimus doubled PFS vs SOC ET + everolimus post-CDK4/6 in HR+/HER2– MBC ESR1 mut population; 10 mo vs 5.4 mo in ESR1-mut tumors. No major benefit in ESR1-WT sub-analysis.

Another fantastic discussion in the advanced #BreastCancer oral abstract session at #ESMO2025 by the great Javier Cortes MD PhD on the available data with #ADC for both HR+/HER2- and HER2- disease OncoAlert ESMO - Eur. Oncology #bcsm

The KM curve of 2025: among high risk patients with HER2+ eBC and RD, adjuvant T-DXd halved the risk of recurrence vs T-DM1. New SoC for pts with: -inoperable disease at diagnosis -node-positive RD 10.8% rate of ILD, 3 deaths. Remember to monitor the lungs! #ESMOAmbassadors

Expert opinion Luca Malorni tackling endocrine resistance in metastatic ER+ breast cancer. #ESMO25

#ESMO25 Breaking the 6-Month PFS Ceiling after CDK4/6 Inhibition